Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
This article was originally published in The Pink Sheet Daily
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.
You may also be interested in...
Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
Celldex presented positive data from a Phase II study testing the therapeutic cancer vaccine Rintega in patients with EGFRvIII-positive recurrent glioblastoma, including a survival advantage, at ASCO.
Earnings Updates, In Brief: Alkermes, Celldex, Jazz, United Therapeutics, Bayer
Alkermes discontinues development of a Phase I pain drug but is on track with schizophrenia drug launch; Celldex gains “breakthrough” designation for rindopepimut; Jazz halts a mid-stage trial due to safety issues; United Therapeutics talks up PAH drug; and Bayer CEO slams German government for lack of VC support.
Immunotherapy: Big Pharma’s Seductive Embrace
The oncology community believes that immunotherapy will be foundational, in the same way that combination chemotherapy became the backbone of treatment in the 1970s. The marching order is to trial broadly, quickly, making clinical development particularly well-suited for Big Pharma.